These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27792859)

  • 21. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.
    Altrock PM; Brendel C; Renella R; Orkin SH; Williams DA; Michor F
    Am J Hematol; 2016 Sep; 91(9):931-7. PubMed ID: 27299299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the current status of gene therapy for primary immune deficiencies (PIDs).
    Kuo CY; Kohn DB
    J Allergy Clin Immunol; 2020 Aug; 146(2):229-233. PubMed ID: 32771134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of autologous blood cell therapies.
    Kim AR; Sankaran VG
    Exp Hematol; 2016 Oct; 44(10):887-94. PubMed ID: 27345108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Editing: Regulatory and Translation to Clinic.
    Ando D; Meyer K
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):797-808. PubMed ID: 28895848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing precision medicine using scarless genome editing of human pluripotent stem cells.
    Steyer B; Cory E; Saha K
    Drug Discov Today Technol; 2018 Aug; 28():3-12. PubMed ID: 30205878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy of hematological disorders: current challenges.
    Al-Saif AM
    Gene Ther; 2019 Aug; 26(7-8):296-307. PubMed ID: 31300728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Special Education: Aplastic Anemia.
    Teramura M; Mizoguchi H
    Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias.
    Shefer Averbuch N; Steinberg-Shemer O; Dgany O; Krasnov T; Noy-Lotan S; Yacobovich J; Kuperman AA; Kattamis A; Ben Barak A; Roth-Jelinek B; Chubar E; Shabad E; Dufort G; Ellis M; Wolach O; Pazgal I; Abu Quider A; Miskin H; Tamary H
    Eur J Haematol; 2018 Sep; 101(3):297-304. PubMed ID: 29786897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smoothing the crescent curve: sickle cell disease.
    Talano JA; Cairo MS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):468-74. PubMed ID: 25696896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induced Pluripotency and Gene Editing in Fanconi Anemia.
    Navarro S; Giorgetti A; Raya A; Tolar J
    Curr Gene Ther; 2017; 16(5):321-328. PubMed ID: 28103772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cell therapeutics and gene therapy for neurologic disorders.
    Chen KS; Koubek EJ; Sakowski SA; Feldman EL
    Neurotherapeutics; 2024 Jul; 21(4):e00427. PubMed ID: 39096590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.
    Yu KR; Natanson H; Dunbar CE
    Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating hemoglobinopathies using gene-correction approaches: promises and challenges.
    Cottle RN; Lee CM; Bao G
    Hum Genet; 2016 Sep; 135(9):993-1010. PubMed ID: 27314256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy.
    Kohn DB
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):721-735. PubMed ID: 28895843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Congenital Anemias.
    Steinberg-Shemer O; Tamary H
    Mol Diagn Ther; 2020 Aug; 24(4):397-407. PubMed ID: 32557003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.